Tiziana Life Sciences to present two studies featuring StemPrintER, a stem cell biology-based Breast Cancer Prognostic Tool d...
May 11 2020 - 2:00AM
Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the
“Company”), a biotechnology company focused on innovative
therapeutics for inflammatory and autoimmune diseases, announces
that two abstracts on the Company’s stem cell biology-based genomic
tool, StemPrintER, for the prediction of disease recurrence in
breast cancer patients, will be presented at the American Society
of Clinical Oncology’s 2020 Virtual Conference. All
abstracts, including Abstract #1020, which compares Tiziana’s
product to current market leader Oncotype DX as part of a poster
discussion session, will be available online beginning May 13, 2020
beginning at 5:00 PM ET at abstracts.asco.org. The American
Society of Clinical Oncology (ASCO) Virtual Conference will be held
from May 29-31, 2020.
In addition, the Company will publish online two
e-abstracts featuring its Miliciclib compound for the treatment of
hepatocellular carcinoma on 13 May 2020 but which will not be
presented as part of the conference.
Abstracts include:
Poster Discussion Session, Breast
Cancer, Metastatic:
- Abstract #1020: “Comparison of StemPrintER, a novel
biology-based genomic predictor of distant recurrence in breast
cancer, with Oncotype DX in the TransATAC cohort”
Poster Session, Breast Cancer,
Metastatic:
- Abstract #1057: “Integration of the stem cell biology-based
genomic tool, StemPrintER, with clinicopathological parameters for
the prediction of distant recurrence in ER+/HER2- breast cancer
(BC) patients”
e-Abstracts include:
- e16711: “Phase 2a safety and efficacy of Milciclib, a
pan-cyclin dependent kinase inhibitor, in unresectable,
sorafenib-refractory or -intolerant hepatocellular carcinoma
patients”
- e16634: “Safety and clinical activity of combination treatment
with regorafenib and milciclib in liver transplant patients with
hepatocellular carcinoma recurrence”
“These data being presented at ASCO are
significant for our oncology portfolio and highlight a
complementary technology for detection of breast cancer,” said Dr.
Kunwar Shailubhai, CEO & CSO of Tiziana Life Sciences.
“Of particular note is that one of these studies was selected to be
part of a poster discussion session during the meeting. We
look forward to sharing these critical data on our StemPrintER
clinical diagnostic for ER+/HER2- breast cancer patients and its
utility in potentially optimizing therapeutic decision-making,
especially in the discussion of StemPrintER relative to the current
market leader, Oncotype DX.”
About StemPrintERStemPrintER is
a multi-gene prognostic assay intended for the prediction of the
risk of recurrence in luminal, estrogen receptor-positive
HER2-negative breast cancer patients, based on the detection of 20
cancer stem cell markers. The assay has been evaluated in an
initial retrospective validation study using a consecutive cohort
of approximately 2,400 patients with breast cancer.
About MilciclibMilciclib is a
potent, small molecule inhibitor of multiple cyclin-dependent
kinases (CDKs), tropomycin receptor kinases and Src family kinases
controlling cell growth and malignant progression of cancer.
Milciclib has demonstrated safety in 316 patients with advanced
solid cancers in Phase I and II studies and shown indications of
efficacy. In two completed Phase II thymic cancer trials, Milciclib
successfully increased overall survival and met both primary and
secondary endpoints. While the current standard of care for
hepatocellular carcinoma (HCC), the most common liver cancer, is
only effective in a small percentage of patients, Milciclib has the
potential to be broadly effective because it targets the underlying
cause of disease. A unique feature of Milciclib is its ability to
reduce microRNAs, miR-221 and miR-222, that promote the formation
of blood vessels (angiogenesis) to facilitate the spread of cancer
cells. Levels of these microRNAs are consistently increased in HCC
patients and may contribute towards resistance to treatment with
Sorafenib.
About Tiziana Life
SciencesTiziana Life Sciences plc is a UK biotechnology
company that focuses on the discovery and development of novel
molecules to treat human disease in oncology and immunology. In
addition to Milciclib, the Company is also developing Foralumab for
liver diseases. Foralumab is the only fully human anti-CD3
monoclonal antibody in clinical development in the world. This
Phase 2 compound has potential application in a wide range of
autoimmune and inflammatory diseases, multiple sclerosis, type-1
diabetes (“T1D”), Crohn’s disease, psoriasis and rheumatoid
arthritis, where modulation of a T-cell response is desirable.
Receive news and updates from Tiziana Life
Sciences plc by signing up to get email alerts
at https://ir.tizianalifesciences.com.
Forward-Looking
StatementsCertain statements made in this announcement are
forward-looking statements. These forward-looking statements are
not historical facts but rather are based on the Company’s current
expectations, estimates, and projections about its industry; its
beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’
‘intends,’ ‘plans,’ ‘believes,’ ’seeks,’ ‘estimates,’ and similar
expressions are intended to identify forward-looking statements.
These statements are not guarantees of future performance and are
subject to known and unknown risks, uncertainties, and other
factors, some of which are beyond the Company’s control, are
difficult to predict, and could cause actual results to differ
materially from those expressed or forecasted in the
forward-looking statements. The Company cautions security holders
and prospective security holders not to place undue reliance on
these forward-looking statements, which reflect the view of the
Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
Contacts:Tiziana Life Sciences
plc
United Kingdom:Gabriele
Cerrone, Chairman and founder +44 (0)20 7495 2379
Cairn Financial Advisers LLP (Nominated
adviser)Liam Murray / Jo Turner + 44 (0)20 7213 0883
Shore Capital (Broker)Antonio Bossi / Fiona
Conroy +44 (0)20 7601 6125
United States:InvestorsCORE
IRir@coreir.com
MediaJules AbrahamCORE IR(917)
885-7378julesa@coreir.com
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Sep 2023 to Sep 2024